Please login to the form below

Not currently logged in
Email:
Password:

Biocon

This page shows the latest Biocon news and features for those working in and with pharma, biotech and healthcare.

Roche’s Herceptin/Perjeta fixed-dose combo filed with FDA

Roche’s Herceptin/Perjeta fixed-dose combo filed with FDA

Amgen launched its Kamjinti there in July, with Biocon and Mylan reaching the market with their Ogivri biosimilar in December, and others are in the latter stages of regulatory review.

Latest news

More from news
Approximately 10 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • Deal Watch May 2016 Deal Watch May 2016

    Similarly, Bristol-Myers Squibb has called time on its deal with Biocon for IN-105/Tregopil [oral insulin]. ... Given the cost of the clinical studies going forwards, Biocon will now be seeking a new partner.

  • Pharma deals during February 2013 Pharma deals during February 2013

    Biosimilars continue to attract. Mylan's third Indian deal is in biosimilars, as it sets up an exclusive strategic collaboration with Biocon for three insulin biosimilars: Biocon's Glargine (the generic ... Mylan and Biocon will share development and

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mednet Group

Communique Small consultancy of the year 2020. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC...

Latest intelligence

Menopause-thumbnail.png
Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...